ENGIMATA INC
Company Details
Status: Private
Employees: 1-10
Location:
Pleasanton, California, United States
Type:
sample
Technology:
sample
About: Engimata has a platform adjuvant technology that improves vaccine efficiency, reduces antigen dose and enhances vaccine stability outside the cold supply chain. Engimata is currently developing a vaccine against COVID-19 using its platform technology. Engimata’s vaccine is cost-effective, easy to scale up, and simple to manufacture and distribute outside the cold supply chain. This increases vaccine accessibility and stability, ultimately saving cost, resources, and lives. Vaccine wastage in the supply chain due to temperature fluctuations is a major problem for current vaccines and costs the government and WHO billions of dollars every year. In order to combat COVID-19, it is crucial to overcome transportation barriers and distribute a vaccine across the world.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
ENGIMATA INC | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.